Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities
Novartis began construction on a 46,000 sq. ft radioligand therapy (RLT) manufacturing site in Denton, Texas, as part of a $23 billion US investment to expand cancer treatment production. The facility, operational by 2028, will be the fifth US RLT site and aims to improve access to personalized cancer therapies in the southern US while creating local jobs.
Novartis officially broke ground on its new radioligand therapy (RLT) manufacturing facility in Denton, Texas, on May 7, 2026. This marks the latest step in the company’s $23 billion commitment to expand US-based research and manufacturing, with the Texas site set to become operational in 2028. The 46,000 sq. ft facility will be the fifth US RLT production site, joining existing locations in New Jersey, Indiana, California, and a new Florida site, creating a coast-to-coast network for delivering highly personalized cancer treatments. The Denton facility aims to bring RLT production closer to patients across the southern US, ensuring timely access to therapies that are custom-made for each patient. Vas Narasimhan, Novartis CEO, emphasized the importance of expanded manufacturing in scaling these treatments, particularly as they are increasingly used in earlier cancer stages. The site will support new jobs in bioengineering, advanced manufacturing, quality, and operations, contributing to economic growth in North Texas. US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent Hagenbuch, and local officials joined Novartis leadership to celebrate the groundbreaking. Senator Hagenbuch highlighted Denton’s appeal as a location with a skilled workforce and proximity to a rapidly growing population. The facility will reinforce Novartis’ role as the first company to deliver RLT at scale, ensuring over 99% of doses are administered on schedule. Construction on the Denton site follows the announcement of seven new and three expanded US facilities as part of Novartis’ broader plan to manufacture key medicines domestically. The company’s April 2025 commitment includes a new site in Morrisville, North Carolina, focused on active pharmaceutical ingredients for solid dosage tablets, capsules, and RNA therapeutics. The Denton groundbreaking underscores rapid progress in the company’s US investment strategy, aiming to strengthen supply resilience and patient access to life-saving treatments.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.